Department of Conservative Dentistry with Endodontics, Institute of Dentistry, Jagiellonian University Medical College, 31-155 Kraków, Poland.
Department of Epidemiology and Population Studies, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, 31-066 Kraków, Poland.
Int J Environ Res Public Health. 2021 Jan 18;18(2):770. doi: 10.3390/ijerph18020770.
The goal of the study was to assess the relationship between cardioprotective medications, i.e., beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), angiotensin II receptor blockers (ARBs), statins, acetylsalicylic acid (ASA), and periodontitis (PD).
Xerostomia increases the risk of PD and is a side effect of some pharmacotherapies. Information about the effect of cardioprotective treatment of periodontal status is scarce.
We studied 562 dentate residents of Krakow at the age of 50 to 70 years. Information about treatment was collected using a standardized questionnaire. The pocket depth and clinical attachment level (CAL) were used to ascertain PD. Multivariate logistic regression was applied to assess the relation between cardioprotective medications and PD.
PD was found in 74% of participants. The range of cardioprotective drug use among participants was 7% (ARBs) to 32% (beta-blockers). After adjusting for age, sex, number of teeth, smoking, and education, ASA's use was related to a lower prevalence of PD in all dentate participants (odds ratio (OR) = 0.63, 95% confidence interval (CI): 0.40-0.99). The use of ARBs and statins was found to be associated with a higher prevalence of PD in persons having ≥6 teeth (odds ratio (OR) = 3.57, 95% CI: 1.06-11.99 and OR = 1.81, 95% CI: 1.03-3.16, respectively). Further adjustment for CVD risk factors, history of coronary heart disease, and other chronic diseases did not attenuate the results. There was no significant relation between PD and the use of other cardioprotective drugs.
评估心脏保护药物（即β受体阻滞剂、血管紧张素转换酶抑制剂（ACEI）、钙通道阻滞剂（CCB）、血管紧张素 II 受体阻滞剂（ARB）、他汀类药物、乙酰水杨酸（ASA）和牙周炎（PD）之间的关系。
口干症会增加 PD 的风险，并且是某些药物治疗的副作用。关于心脏保护治疗对牙周状况影响的信息很少。
我们研究了 562 名年龄在 50 至 70 岁的克拉科夫有牙居民。使用标准化问卷收集有关治疗的信息。使用牙周袋深度和临床附着水平（CAL）来确定 PD。应用多变量逻辑回归评估心脏保护药物与 PD 之间的关系。
74%的参与者患有 PD。参与者中使用的心脏保护药物的范围为 7%（ARB）至 32%（β受体阻滞剂）。在调整年龄、性别、牙齿数量、吸烟和教育程度后，ASA 的使用与所有有牙参与者 PD 的患病率降低相关（比值比（OR）=0.63，95%置信区间（CI）：0.40-0.99）。使用 ARB 和他汀类药物与有≥6 颗牙齿的人 PD 患病率升高相关（OR=3.57，95%CI：1.06-11.99 和 OR=1.81，95%CI：1.03-3.16）。进一步调整心血管疾病危险因素、冠心病史和其他慢性病并没有减弱这些结果。PD 与其他心脏保护药物的使用之间没有显著关系。
